The trial design of EMD AML has been explained as due to the positive response to Zantrene and the better potential recruitment given no other trials were focused on this area noting that AML trial space is overcrowded/competitive. Initially, I believe, management were advised recruitment should be reasonable by their trial partners but it has not turned out that way particularly in Australia due to the issue of scans not being considered by clinicians (even though Race offered to pay). The trial design seemed quite well thought out for the circumstances. I do have some questions around old formula vs new formula Zantrene and the rule it has played, if any, and whether it makes sense to continue if close at hand. Might get to DCB on that one....
- Forums
- General
- General Comments / Chat
The trial design of EMD AML has been explained as due to the...
-
- There are more pages in this discussion • 3,664 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.70 |
Change
0.050(3.03%) |
Mkt cap ! $289.6M |
Open | High | Low | Value | Volume |
$1.66 | $1.70 | $1.63 | $181.9K | 109.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 11946 | $1.70 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.75 | 27579 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6605 | 1.635 |
1 | 10752 | 1.615 |
2 | 20016 | 1.610 |
2 | 21000 | 1.600 |
1 | 1279 | 1.555 |
Price($) | Vol. | No. |
---|---|---|
1.750 | 14579 | 3 |
1.755 | 990 | 1 |
1.760 | 500 | 1 |
1.800 | 824 | 2 |
1.820 | 4000 | 3 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online